



GMMM Interface Prescribing
Subgroup



Agenda

12th March 2015, 1pm-3pm

HMR CCG

Meeting Room 1, Croft Shifa Health Centre, Belfield Road, Rochdale OL16 2UY

[Declarations of Interest](#) (new declarations only)

Apologies:

	ENC
1) Draft Minutes of 12th February 2015	Item 1
2) Matters Arising <ul style="list-style-type: none"> a) RAG List Review - Drugs for alcohol dependence (nalmeferene, acamprosate and disulfiram) b) RAG List Recommendations from Oct meeting – now GMMM approved except LMWH c) RAG List Recommendations from Chapter 4 - now GMMM approved d) RAG List Recommendations from January meeting – awaiting GMMM approval e) RAG List Recommendations from February meeting (Domperidone, Chapter 6 and 11) – comments received f) Antidementia drugs leaflets – awaiting GMMM approval g) Chapter 10 SCP Protocol Review h) Chapter 9 SCP Review - hydroxycarbamide i) Chapter 5 SCP Review - colistimethate for non-CF patients j) Chapter 4 SCP Review – ADHD Drugs <ul style="list-style-type: none"> - Melatonin SCP - now GMMM approved k) Chapter 6 SCP Review – Ibandronate for breast cancer l) Transgender use of hormone therapy 	Item 2a Item 2e Item 2k Item 2l
3) Chapter 3 RAG list review – drugs for review <ul style="list-style-type: none"> a) Dornase alfa – currently Amber – should be changed to Red b) Omalizumab – currently Red c) Bee & wasp allergen (Pharmalgen®) – no status 	Item 3

<ul style="list-style-type: none"> d) Pirfenidone – no status (currently Red on the formulary) e) C1-esterase inhibitor – no status f) Conestat alfa – no status g) Icatibant – no status h) Ivacaftor – no status i) Grass Pollen Extract – no status j) Poractant alfa (Curosurf®) – no status k) Mannitol inhaler – no status l) Salbutamol injection – no status (currently Red on the formulary) m) Aminophylline injection – no status n) Azathioprine for interstitial lung disease – no status 													
<p>4) Chapter 3 Shared Care Protocol review – existing guidelines</p> <table border="1" data-bbox="193 730 1278 898"> <thead> <tr> <th data-bbox="193 730 632 831">Document Title</th> <th data-bbox="632 730 727 831">BNF</th> <th data-bbox="727 730 935 831">Organisation</th> <th data-bbox="935 730 1031 831">Date</th> <th data-bbox="1031 730 1158 831">Review date</th> <th data-bbox="1158 730 1278 831">In GMMMG Format</th> </tr> </thead> <tbody> <tr> <td data-bbox="193 831 632 898">Pulmozyme 2500 U/ 2.5 ml, nebuliser solution in CF patients</td> <td data-bbox="632 831 727 898">3</td> <td data-bbox="727 831 935 898">UHSM</td> <td data-bbox="935 831 1031 898">Feb 2013</td> <td data-bbox="1031 831 1158 898">?</td> <td data-bbox="1158 831 1278 898">Yes</td> </tr> </tbody> </table>	Document Title	BNF	Organisation	Date	Review date	In GMMMG Format	Pulmozyme 2500 U/ 2.5 ml, nebuliser solution in CF patients	3	UHSM	Feb 2013	?	Yes	Item 4
Document Title	BNF	Organisation	Date	Review date	In GMMMG Format								
Pulmozyme 2500 U/ 2.5 ml, nebuliser solution in CF patients	3	UHSM	Feb 2013	?	Yes								
<p>5) Chapter 3 Shared Care Protocol review – drugs without an SCP None</p>													
<p>6) Chapter 12 RAG List Review and Shared Care Protocol Review Currently no drugs classified as Red or Amber, and no SCPs.</p>													
<p>7) Chapter 13 RAG list review – drugs for review</p> <ul style="list-style-type: none"> a) Acitretin – currently Red b) Alitretinoin – currently Red c) Botulinum toxin – currently Red d) Isotretinoin (oral) – currently Red e) Tacrolimus ointment – no status (For initiation by specialist only on formulary) f) Pimecrolimus – no status (For initiation by specialist only on formulary) g) Dithranol (licensed preps) – no status h) Dithranol (unlicensed preps) – no status i) Ustekinumab – no status j) Dapsone – no status k) DMARDs when used in dermatology (Ciclosporin, Oral Methotrexate, Azathioprine, Mycophenolate) – no status 	Item 7												
<p>8) Chapter 13 Shared Care Protocol review – existing guidelines None</p>													
<p>9) Strontium – review of RAG status</p>	Item 9												
<p>10) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status</p> <ul style="list-style-type: none"> a) DuoResp® (Budesonide/formoterol) inhaler b) Tapentadol – not for routine prescribing & FSG added to Grey list. 													

c) Relvar® inhaler	
11) Shared Care Protocols for Approval • Cinacalcet primary hyperparathyroidism	Item 10
12) Forward work plan	Item 11
13) Updates from other groups	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMG (verbal) – LHRH analogues in prostate cancer SCP now GMMMG approved.	
14) AOB	
Date of Next Meeting: 9th April 2015, 1pm-3pm Room 410, HMR CCG, Number One Riverside, Smith St Rochdale OL16 1XU	